BR9909420A - Composto, kit, composição metalofarmacêutica de diagnóstico ou terapêutica, composição de agente de contraste de ultrassom, composição radiofarmacêutica terapêutica e composição radiofarmacêutica de diagnóstico - Google Patents

Composto, kit, composição metalofarmacêutica de diagnóstico ou terapêutica, composição de agente de contraste de ultrassom, composição radiofarmacêutica terapêutica e composição radiofarmacêutica de diagnóstico

Info

Publication number
BR9909420A
BR9909420A BR9909420-7A BR9909420A BR9909420A BR 9909420 A BR9909420 A BR 9909420A BR 9909420 A BR9909420 A BR 9909420A BR 9909420 A BR9909420 A BR 9909420A
Authority
BR
Brazil
Prior art keywords
composition
therapeutic
contrast agent
diagnostic
radiopharmaceutical
Prior art date
Application number
BR9909420-7A
Other languages
English (en)
Inventor
Miland Rajopadhye
Scott D Edwards
Thomas D Harris
Stuart J Heminway
Shuang Liu
Prahlad R Singh
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of BR9909420A publication Critical patent/BR9909420A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSTO, KIT, COMPOSIçãO METALOFARMACêUTICA DE DIAGNóSTICO OU TERAPêUTICA, COMPOSIçãO DE AGENTE DE CONTRASTE DE ULTRASSOM, COMPOSIçãO RADIOFARMACêUTICA TERAPêUTICA E COMPOSIçãO RADIOFARMACêUTICA DE DIAGNóSTICO" A presente invenção descreve compostos inovadores da fórmula (Q)~ d~-L~ n~-C~ h~, úteis para o diagnóstico e tratamento de câncer, métodos de formação de imagens de tumores em pacientes e métodos de tratamento de câncer em pacientes. A presente invenção também proporciona compostos inovadores úteis para o monitoramento do tratamento terapêutico de angiogênese e destruição de nova vasculatura angiogênica. Os produtos farmacêuticos são compostos de uma porção desejada que se une a um receptor que é regulado para cima durante a angiogênese, um grupo opcional de ligação e um radioisótopo terapeuticamente eficaz ou porção representável diagnosticamente eficaz. A porção representável é um radioisótopo emissor de raio gama ou positron, um agente de contraste de formação de imagens por ressonância magnética, um agente de contraste de raio X ou um agente de contraste de ultrassom.
BR9909420-7A 1998-03-31 1999-03-29 Composto, kit, composição metalofarmacêutica de diagnóstico ou terapêutica, composição de agente de contraste de ultrassom, composição radiofarmacêutica terapêutica e composição radiofarmacêutica de diagnóstico BR9909420A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8015098P 1998-03-31 1998-03-31
US11271598P 1998-12-18 1998-12-18
PCT/US1999/006826 WO1999058162A2 (en) 1998-03-31 1999-03-29 Pharmaceuticals for the imaging of angiogenic disorders

Publications (1)

Publication Number Publication Date
BR9909420A true BR9909420A (pt) 2001-09-25

Family

ID=26763137

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909420-7A BR9909420A (pt) 1998-03-31 1999-03-29 Composto, kit, composição metalofarmacêutica de diagnóstico ou terapêutica, composição de agente de contraste de ultrassom, composição radiofarmacêutica terapêutica e composição radiofarmacêutica de diagnóstico

Country Status (20)

Country Link
US (2) US20020001566A1 (pt)
EP (1) EP1068224B1 (pt)
JP (1) JP4487019B2 (pt)
KR (1) KR20010042288A (pt)
CN (1) CN1295578A (pt)
AR (1) AR020586A1 (pt)
AT (1) ATE295369T1 (pt)
AU (1) AU5541799A (pt)
BR (1) BR9909420A (pt)
CA (1) CA2324555A1 (pt)
DE (1) DE69925262T2 (pt)
EA (1) EA200001007A1 (pt)
EE (1) EE200000574A (pt)
ES (1) ES2241313T3 (pt)
HU (1) HUP0101468A2 (pt)
IL (1) IL138093A0 (pt)
NO (1) NO20004917L (pt)
PL (1) PL343804A1 (pt)
SK (1) SK13952000A3 (pt)
WO (1) WO1999058162A2 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
EP1281068B1 (en) * 2000-05-08 2008-03-26 TTP LabTech Ltd Microphysiometer
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
EP1289565B1 (en) 2000-06-02 2015-04-22 Bracco Suisse SA Compounds for targeting endothelial cells
EP1296678A2 (en) * 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
CA2413328A1 (en) * 2000-06-21 2001-12-27 Milind Rajopadhye Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
WO2002004030A2 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions
EP1337278A2 (en) 2000-11-27 2003-08-27 Bristol-Myers Squibb Medical Imaging, Inc. Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7271180B2 (en) * 2001-01-23 2007-09-18 Wyeth 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US7589061B2 (en) 2001-04-23 2009-09-15 Mallinckrodt Inc. Tc and Re labeler radioactive glycosylated octreotide derivatives
US7138104B2 (en) * 2001-08-08 2006-11-21 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
CA2464472C (en) 2001-10-22 2014-01-07 The Scripps Research Institute Antibody targeting compounds
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
BR0307206A (pt) 2002-01-24 2004-12-21 Barnes Jewish Hospital Agentes de formação de imagem direcionados por integrina
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP1572724A4 (en) * 2002-03-01 2007-03-14 Dyax Corp KDR AND VEGF / KDR BINDING SPEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US20050100963A1 (en) * 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
AU2003235489A1 (en) * 2002-05-08 2003-11-11 Tom Mcneil High efficiency solid-state light source and methods of use and manufacture
US6961607B2 (en) * 2002-07-31 2005-11-01 Uzgiris Egidijus E Method for assessing myocardial angiogenesis
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
AU2003265898A1 (en) * 2002-09-05 2004-03-29 Genentech, Inc. Infusion catheter having an integrated doppler transducer
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
US7531622B2 (en) * 2002-09-19 2009-05-12 Centre National De La Recherche Scientifique- Cnrs Synthesis and characterization of novel systems for guidance and vectorization of molecules of therapeutic interest towards target cells
WO2004069281A1 (en) * 2003-01-30 2004-08-19 The General Hospital Corporation Bifunctional molecules comprising at least one integrin-binding and their use in imaging and therapy of angiogenesis and related disorders
AU2004217894B2 (en) 2003-03-03 2010-07-15 Bracco International B.V. Peptides that specifically bind HGF receptor (cMet) and uses thereof
CA2525396A1 (en) * 2003-05-12 2004-11-25 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals
EP1651276A4 (en) * 2003-08-08 2009-05-06 Barnes Jewish Hospital EMULSION PARTICLES FOR IMAGING AND THERAPY AND USE METHOD THEREFOR
WO2005016387A2 (en) * 2003-08-12 2005-02-24 University Of Iowa Research Foundation Dna-dependent mri contrast agents
JP2007517874A (ja) * 2004-01-16 2007-07-05 バーンズ−ジューイッシュ ホスピタル 標的化アテローム性動脈硬化症治療法
EP1720887B1 (en) * 2004-02-23 2008-04-02 Dow Gloval Technologies Inc. Aqueous-based adhesive for bonding low surface energy substrates
AU2005253962A1 (en) 2004-06-09 2005-12-29 Kereos, Inc. Lipophilic derivatives of chelate monoamides
ATE359496T1 (de) * 2004-07-02 2007-05-15 Vivactis Nv Messung der wärme erzeugt durch einen chemischen oder biologischen prozess.
EP1861127A1 (en) * 2005-03-10 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
US20090131327A1 (en) * 2005-04-29 2009-05-21 Patrick Doherty Nogo receptor functional motifs and peptide mimetics related thereto and methods of using the same
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
US20070140973A1 (en) * 2005-12-15 2007-06-21 Bristol-Myers Squibb Pharma Company Contrast agents for myocardium perfusion imaging
US20070258908A1 (en) * 2006-04-27 2007-11-08 Lanza Gregory M Detection and imaging of target tissue
EP2076120A1 (en) * 2006-09-29 2009-07-08 Washington University Combinations for treatment of neovasculature
WO2008073842A1 (en) * 2006-12-08 2008-06-19 Molecular Image Inc. Methods for diagnosis and monitoring of neurologic diseases using magnetic resonance methods
US8194963B2 (en) * 2008-03-10 2012-06-05 Siemens Medical Solutions Usa, Inc. Efficient estimator of pharmacokinetic parameters in breast MRI
CN102088991A (zh) 2008-05-13 2011-06-08 堪萨斯大学 金属提取肽标签和相关方法
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
CA2907506C (en) * 2013-03-27 2022-09-20 Theranos, Inc. Biological sample processing
EP3335721A1 (en) * 2013-04-12 2018-06-20 Evox Therapeutics Limited Therapeutic delivery vesicles
DE102013113156A1 (de) * 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
KR102548998B1 (ko) * 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
DE3360633D1 (en) 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IL91933A (en) 1988-10-11 1994-12-29 Univ Southern California Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue
EP0534944B1 (en) 1988-11-14 1996-09-11 Brigham And Women's Hospital Antibodies specific for elam-1 and the use thereof
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
EP0422186B1 (en) 1989-04-10 1998-12-09 Oncogen Limited Partnership Use of oncostatin m for suppressing mhc antigens
US5395609A (en) 1989-06-19 1995-03-07 Antisoma Limited Synthetic peptides for use in tumor detection
DE69018226T2 (de) 1989-07-20 1995-09-21 Sandoz Ag Markierte polypeptidderivate.
IN172208B (pt) 1990-04-02 1993-05-01 Sint Sa
WO1993008210A1 (en) 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
DE4301871A1 (de) 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5744120A (en) 1993-03-30 1998-04-28 The Dupont Merick Pharmaceutical Company Ternary radiopharmaceutical complexes
DE4311023C2 (de) 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
WO1995003280A1 (en) 1993-07-19 1995-02-02 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0762882A4 (en) 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
PT771216E (pt) 1994-07-11 2001-07-31 Scripps Research Inst Metodos e composicoes para a coagulacao especifica da vasculatura tumoral
CA2230209A1 (en) 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
DE19536785A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ S¶2¶NY für radioaktive Isotope
DE19536781A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope
DE69628731T3 (de) * 1995-11-01 2012-09-20 Bracco Suisse S.A. Gezielte magnetisch markierte molekularmarkersysteme als nmr-bilderzeugungsmittel
BR9611563A (pt) 1995-11-14 1999-03-02 Du Pont Merck Pharma Composto composição farmacêutica método de tratamento de uma doença inflamatória e ensaio para detectar inibidores de agrecanase
US6331285B1 (en) * 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
ZA978758B (en) * 1996-10-02 1999-03-30 Du Pont Merck Pharma Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU4753997A (en) * 1996-10-16 1998-05-11 Burnham Institute, The Magnetic resonance imaging of thrombi
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
WO1998018497A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
DE19725368A1 (de) * 1997-06-16 1998-12-17 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren und deren Verwendung für bildgebende Verfahren
EP1015884B1 (en) * 1997-09-10 2008-08-06 The Burnham Institute Methods of identifying molecules that home to angiogenic vasculature in tumors
AU757554B2 (en) * 1998-02-11 2003-02-27 Bracco International B.V. Angiogenesis targeting molecules
JP2002521450A (ja) 1998-07-29 2002-07-16 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト

Also Published As

Publication number Publication date
NO20004917L (no) 2000-11-02
CN1295578A (zh) 2001-05-16
US6322770B1 (en) 2001-11-27
EE200000574A (et) 2002-10-15
AU5541799A (en) 1999-11-29
AR020586A1 (es) 2002-05-22
DE69925262D1 (de) 2005-06-16
ES2241313T3 (es) 2005-10-16
SK13952000A3 (sk) 2001-12-03
EP1068224A2 (en) 2001-01-17
PL343804A1 (en) 2001-09-10
JP4487019B2 (ja) 2010-06-23
WO1999058162A3 (en) 2000-04-06
EA200001007A1 (ru) 2001-04-23
NO20004917D0 (no) 2000-09-29
US20020001566A1 (en) 2002-01-03
IL138093A0 (en) 2001-10-31
WO1999058162A2 (en) 1999-11-18
EP1068224B1 (en) 2005-05-11
ATE295369T1 (de) 2005-05-15
JP2002514611A (ja) 2002-05-21
KR20010042288A (ko) 2001-05-25
HUP0101468A2 (hu) 2001-08-28
CA2324555A1 (en) 1999-11-18
DE69925262T2 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
BR9909420A (pt) Composto, kit, composição metalofarmacêutica de diagnóstico ou terapêutica, composição de agente de contraste de ultrassom, composição radiofarmacêutica terapêutica e composição radiofarmacêutica de diagnóstico
Bombardieri et al. Bone scintigraphy: procedure guidelines for tumour imaging
Inoue et al. 18F α-methyl tyrosine PET studies in patients with brain tumors
Meredith et al. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1, k 17-1A monoclonal antibody
BR9917079A (pt) Compostos antagonistas de receptor devitronectina, kit, composição metalofarmacêuticade diagnóstico ou terapêutica, composição deagente de contraste para ultra-som, composiçãoradiofarmacêutica terapêutica, composiçãofarmacêutica de diagnóstico, método detratamento da artrite reumatóide, do cancêr e darestenose em um paciente, método de formação deimagem da angiogênese terapêutica, do câncer, denovos vasos sanguìneos, da arteriosclerose, darestenose, da isquemia e da lesão por reperfusãodo miocárdio em um paciente
Kobayashi et al. Soft-tissue tumors: diagnosis with Tc-99m (V) dimercaptosuccinic acid scintigraphy.
Constable et al. Recognition of the superscan in prostatic bone scintigraphy
Leichner et al. Patient-specific dosimetry of indium-111-and yttrium-90-labeled monoclonal antibody CC49
Aigner et al. Parathyroid scintigraphy: comparison of technetium-99m methoxyisobutylisonitrile and technetium-99m tetrofosmin studies
Lear et al. Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column.
Buonocore et al. Positron-emission computed tomography of the pancreas: a preliminary study
Kadam et al. Doughnut sign on FDG-PET scan in a ruptured lung hydatid cyst
Aigner et al. 99Tcm-tetrofosmin scintigraphy in Hodgkin's disease
Tow et al. Scanning for Tumors of Brain and Bone: Comparison of Sodium Pertechnetate Tc 99m and Ionic Strontium 87m
Ryo et al. Adrenal scanning and uptake with 131I-6β-iodomethyl-nor-cholesterol
McQuarrie et al. The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients
Jacobsson et al. Accumulation of FDG in axillary sweat glands in hyperhidrosis: a pitfall in whole-body PET examination
Perkins et al. Gamma camera emission tomography using radiolabelled antibodies
Thrall et al. Discordant imaging of a thyroid nodule with 131I and 99mTc: concordance of 131I and fluorescent scans
Galperin-Aizenberg et al. Renal extramedullary haematopoiesis mimicking renal lymphoma on computed tomography
Ryu et al. Detection of malignant melanoma by Tc-99m HMPAO
Schillaci et al. Technetium-99m tetrofosmin scintigraphy in pediatric osteogenic sarcoma
Grady Molecular Imaging of Infection
Llewellyn et al. Roentgenographically undetectable pulmonary metastases from thyroid carcinoma demonstrated by lung scan
Flynt 18 F Sodium Fluoride: Tracer and Technique

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.